Introduction
Natural products have historically contributed to drug discovery and continue to provide promising therapeutic agents. Despite extensive preclinical evidence, the translation of natural compounds into clinically validated therapies remains limited due to challenges in standardization, bioavailability, and regulatory approval.
Objective
This review aims to critically evaluate clinically validated natural products, elucidate their molecular mechanisms of action, summarize therapeutic applications, and identify key translational challenges hindering their clinical adoption.
Methodology
A comprehensive literature search was conducted using PubMed/MEDLINE, EMBASE, Google Scholar, Scopus, and Web of Science databases. Peer-reviewed articles, clinical trials, systematic reviews, and meta-analyses published in English were included. Relevant keywords related to natural products, clinical validation, pharmacological mechanisms, and translational research were used for data retrieval and analysis.
Results
Several natural products, including polyphenols, alkaloids, terpenoids, and flavonoids, demonstrate significant clinical efficacy across diverse disease conditions such as cancer, metabolic disorders, cardiovascular diseases, and inflammatory conditions. Mechanistically, these compounds modulate key signaling pathways, including NF-κB, PI3K/Akt, MAPK, and oxidative stress pathways. However, clinical translation is often hindered by issues related to pharmacokinetics, dose standardization, variability in bioactive composition, and limited large-scale clinical trials.
Conclusion
Clinically validated natural products hold substantial therapeutic potential, but successful translation into mainstream medicine requires improved standardization, robust clinical evidence, and advanced formulation strategies. Addressing these challenges will facilitate the integration of natural products into evidence-based clinical practice.